The clinical research of bevacizumab combined with FOLFIRI as second-line treatment in advanced colorectal cancer
10.3760/cma.j.issn.1673-4904.2012.35.010
- VernacularTitle:贝伐单抗联合FOLFIRI用于晚期结直肠癌二线治疗的临床研究
- Author:
Xiaohui JING
;
Yunjie GUO
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
Drug therapy,combination;
Bevacizumab;
Irinotecan
- From:
Chinese Journal of Postgraduates of Medicine
2012;(35):29-31
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety ofbevacizumab combined with FOLFIRI regimen as second-line treatment in advanced colorectal cancer.Methods Sixty-five advanced colorectal cancer patients previously treated with oxaliplatin were divided into test group(33 patients) and control group (32 patients) by random digits table method.The patients in test group received bevacizumab combined with FOLFIRI regimen chemotherapy.The patients in control group received FOLFIRI regimen chemotherapy only.The therapeutic effect was evaluated every 4 cycles.Results In test group,1 patient received complete remission,9 patients had partial remission,the rate of efficacy was 30.3％ (10/33).In control group,non patient had complete remission,3 patients received partial remission,the rate of efficacy was 9.4％ (3/32).The rate of efficacy between two groups had significant difference (x2 =4.45,P =0.035).The median duration of survival was 13.0 months in test group,and 10.3 months in control group(HR =0.58,P=0.038).The median progression-free survival duration was 7.5 months in test group,and 4.4 months in control group (HR =0.45,P =0.003).The median treatment cycle was 12 cycles in test group and 8 cycles in control group.The rate of Ⅲ/Ⅳ grade adverse events in test group was higher than that in control group[72.7％(24/33) vs.46.9％ (15/32)] (P ＜ 0.05).None of these events led to death during the study.Conclusions Bevacizumab combined with FOLFIRI as second-line treatment in advanced colorectal cancer can improve the total remission rate,and prolong the progression-free survival duration and total survival duration with an acceptable adverse reaction.
